Patent 7550568 was granted and assigned to University of Pittsburgh on June, 2009 by the United States Patent and Trademark Office.
The present invention provides monoclonal antibodies that react against high molecular weight melanoma-associated antigen. These antibodies may be used for diagnostic and/or therapeutic purposes.